The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex
Abstract
Camptothecin, a cytotoxic antitumor compound, has been shown to produce protein-linked DNA breaks mediated by mammalian topoisomerase I. We have investigated the mechanism by which camptothecin disrupts DNA processing by topoisomerase I and have examined the effect of certain structurally related compounds on the formation of a DNA-topoisomerase I covalent complex. Enzyme-mediated cleavage of supercoiled plasmid DNA in the presence of camptothecin was completely reversed upon the addition of exogenous linear DNA or upon dilution of the reaction mixture. Camptothecin and topoisomerase I produced the same amount of cleavage from supercoiled DNA or relaxed DNA. In addition, the alkaloid decreased the initial velocity of supercoiled DNA relaxation mediated by catalytic quantities of topoisomerase I. Inhibition occurred under conditions favoring processive catalysis as well as under conditions favoring distributive catalysis. By use of [3H]camptothecin and an equilibrium dialysis assay, the alkaloid was shown to bind reversibly to a DNA-topoisomerase I complex, but not to isolated enzyme or isolated DNA. These results are consistent with a model in which camptothecin reversibly traps an intermediate involved in DNA unwinding by topoisomerase I and thereby perturbs a set of equilibria, resulting in increased DNA cleavage. By examining certain compounds that are structurally related to camptothecin, it was found that the 20-hydroxy group, which has been shown to be essential for antitumor activity, was also necessary for stabilization of the covalent complex between DNA and topoisomerase I. In contrast, no such correlation existed for UV-light-induced cleavage of DNA by Cu(II)-camptothecin derivatives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
[57] Sequencing end-labeled DNA with base-specific chemical cleavages
Maxam, A. M., & Gilbert, W. (1980) · Methods in Enzymology · doi:10.1016/s0076-6879(80)65059-9 · Cited by 14,315
Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.
Hsiang, Y. H., Hertzberg, R., Hecht, S., & Liu, L. F. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38654-4 · Cited by 2,362
Self-citationWall, M. E., Wani, M. C., Cook, C. E., Palmer, K. H., McPhail, A. T., & Sim, G. A. (1966) · Journal of the American Chemical Society · doi:10.1021/ja00968a057 · Cited by 2,258
Record, M. T., Anderson, C. F., & Lohman, T. M. (1978) · Quarterly Reviews of Biophysics · doi:10.1017/s003358350000202x · Cited by 1,673
Adriamycin-Induced DNA Damage Mediated by Mammalian DNA Topoisomerase II
Tewey, K. M., Rowe, T. C., Yang, L., Halligan, B. D., & Liu, L. F. (1984) · Science · doi:10.1126/science.6093249 · Cited by 1,538
Tewey, K. M., Chen, G. L., Nelson, E. M., & Liu, L. F. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)47282-6 · Cited by 887
Hsiang, Y. H., & Liu, L. F. (1988) · PubMed · Cited by 841
Nelson, E. M., Tewey, K. M., & Liu, L. F. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.5.1361 · Cited by 558
Eukaryotic DNA topoisomerases: two forms of type I DNA topoisomerases from HeLa cell nuclei.
Liu, L. F., & Miller, K. G. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.6.3487 · Cited by 346
Cited by
Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice
Choudhari, A. S., Mandave, P. C., Deshpande, M., Ranjekar, P., & Prakash, O. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01614 · Cited by 1,086
Crystal Structures of Human Topoisomerase I in Covalent and Noncovalent Complexes with DNA
Redinbo, M. R., Stewart, L., Kuhn, P., Champoux, J. J., & Hol, W. G. J. (1998) · Science · doi:10.1126/science.279.5356.1504 · Cited by 889
The mechanism of topoisomerase I poisoning by a camptothecin analog
Staker, B. L., Hjerrild, K., Feese, M. D., Behnke, C. A., Burgin, A. B., & Stewart, L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242259599 · Cited by 818
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.
ten Bokkel Huinink, W., Gore, M., Carmichael, J., Gordon, A., Malfetano, J., Hudson, I., Broom, C., Scarabelli, C., Davidson, N., Spanczynski, M., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2183 · Cited by 663
DNA-Damaging Agents in Cancer Chemotherapy: Serendipity and Chemical Biology
Cheung-Ong, K., Giaever, G., & Nislow, C. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.04.007 · Cited by 591
Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme
Pommier, Y., Pourquier, P., Fan, Y., & Strumberg, D. (1998) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(98)00129-8 · Cited by 551
Staker, B. L., Feese, M. D., Cushman, M., Pommier, Y., Zembower, D., Stewart, L., & Burgin, A. B. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049146p · Cited by 546
Mechanism of Action of Camptothecin
Liu, L. F., Duann, P., Lin, C., D'Arpa, P., & Wu, J. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb26375.x · Cited by 508
Tumor Cell Death Induced by Topoisomerase-Targeting Drugs
Li, T.-K., & Liu, L. F. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.53 · Cited by 508
Topoisomerase Poisons: Harnessing the Dark Side of Enzyme Mechanism
Froelich-Ammon, S. J., & Osheroff, N. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.37.21429 · Cited by 505
Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme
Burden, D. A., & Osheroff, N. (1998) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(98)00132-8 · Cited by 503
Mechanism of Action of Camptothecin
LIU, L. F., DESAI, S. D., LI, T., MAO, Y., SUN, M., & SIM, S. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb07020.x · Cited by 476
A kinetic and Mechanistic Study of the Hydrolysis of Camptothecin and Some Analogues
Fassberg, J., & Stella, V. J. (1992) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600810718 · Cited by 464
Camptothecin: current perspectives
Thomas, C. J., Rahier, N. J., & Hecht, S. M. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2003.11.036 · Cited by 451
Self-citationComprehensive review on current developments of quinoline-based anticancer agents
Jain, S., Chandra, V., Kumar Jain, P., Pathak, K., Pathak, D., & Vaidya, A. (2019) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2016.10.009 · Cited by 394
Swaminathan, S., Pastero, L., Serpe, L., Trotta, F., Vavia, P., Aquilano, D., Trotta, M., Zara, G., & Cavalli, R. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2009.11.003 · Cited by 358
Lee, M. H., Kim, J. Y., Han, J. H., Bhuniya, S., Sessler, J. L., Kang, C., & Kim, J. S. (2012) · Journal of the American Chemical Society · doi:10.1021/ja303998y · Cited by 309
The long story of camptothecin: From traditional medicine to drugs
Martino, E., Della Volpe, S., Terribile, E., Benetti, E., Sakaj, M., Centamore, A., Sala, A., & Collina, S. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.12.085 · Cited by 296
Clinical Pharmacokinetics of Irinotecan
Chabot, G. G. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199733040-00001 · Cited by 282
Vinculin modulation of paxillin–FAK interactions regulates ERK to control survival and motility
Subauste, M. C., Pertz, O., Adamson, E. D., Turner, C. E., Junger, S., & Hahn, K. M. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200308011 · Cited by 272
Ubiquitin-dependent Destruction of Topoisomerase I Is Stimulated by the Antitumor Drug Camptothecin
Desai, S. D., Liu, L. F., Vazquez-Abad, D., & D'Arpa, P. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.39.24159 · Cited by 269
Disulfide-Based Multifunctional Conjugates for Targeted Theranostic Drug Delivery
Lee, M. H., Sessler, J. L., & Kim, J. S. (2015) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5b00406 · Cited by 254
Site-Specific Ribonuclease Activity of Eukaryotic DNA Topoisomerase I
Sekiguchi, J., & Shuman, S. (1997) · Molecular Cell · doi:10.1016/s1097-2765(00)80010-6 · Cited by 164
Opanasopit, P., Yokoyama, M., Watanabe, M., Kawano, K., Maitani, Y., & Okano, T. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000048190.53439.eb · Cited by 141
Topoisomerase II Binds to Ellipticine in the Absence or Presence of DNA.
Froelich-Ammon, S. J., Patchan, M. W., Osheroff, N., & Thompson, R. B. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.25.14998 · Cited by 137
Watanabe, M., Kawano, K., Yokoyama, M., Opanasopit, P., Okano, T., & Maitani, Y. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.10.030 · Cited by 128
Brezova, V., Valko, M., Breza, M., Morris, H., Telser, J., Dvoranova, D., Kaiserova, K., Varecka, L., Mazur, M., & Leibfritz, D. (2003) · The Journal of Physical Chemistry B · doi:10.1021/jp027743m · Cited by 80
Nanoparticles guided drug delivery and imaging in gastric cancer
Nagaraju, G. P., Srivani, G., Dariya, B., Chalikonda, G., Farran, B., Behera, S. K., Alam, A., & Kamal, M. A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.006 · Cited by 62
LI, X., HALUSKA, P., HSIANG, Y., BHARTI, A., KUFE, D. W., & RUBIN, E. H. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb26381.x · Cited by 21
Metadata
- Authors
- Hertzberg, R. P., Caranfa, M. J., & Hecht, S. M.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1989-05-30
- Volume
- 28
- Issue
- 11
- Pages
- 4629-4638
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2078751203
- Cited by
- 551
- References
- 33
- FWCI
- 2.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.